IBD Infusion-Day Checklist: Medication, Hydration, Symptoms, and Questions

Infusion appointments for inflammatory bowel disease follow a predictable rhythm, which makes them easy to prepare for and easy to waste. You sit in a chair for one to three hours with a nurse who is trained to notice problems, and often the only record of the eight weeks since your last dose is whatever you happen to remember while the IV is being placed. A standing IBD infusion day checklist fixes that. The goal is to arrive with an organized picture of your symptoms, medications, side effects, and questions, so the visit produces useful documentation instead of a blank chart note.

Know Your Drug's Schedule and Infusion Length

Different infusion biologics have different appointment lengths, and knowing yours in advance determines how much time to block off. Infliximab is given as 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks, infused over at least 2 hours. Vedolizumab is 300 mg infused over approximately 30 minutes at weeks 0, 2, and 6, then every 8 weeks. Ustekinumab uses a single weight-based intravenous induction dose of 260, 390, or 520 mg infused over at least one hour before switching to subcutaneous maintenance. Risankizumab induction runs longer, with 600 mg over at least one hour for Crohn's disease and 1,200 mg over at least two hours for ulcerative colitis at weeks 0, 4, and 8. Some centers shorten maintenance infliximab infusions to one hour, and a randomized study in Crohn's & Colitis 360 found accelerated one-hour infusions non-inferior in safety to the standard two-hour protocol. If you have tolerated several infusions without incident, that is a reasonable question to raise.

Hydration and Vein Access

Arriving well hydrated is the single most practical thing you can do to make the stick easier. The strongest predictors of a failed first cannulation attempt are mechanical: in the study that developed the A-DIVA scale, inability to palpate the target vein and inability to see it were the two largest independent predictors of first-attempt failure, along with a vein diameter of 2 millimeters or less and a personal history of difficult access. Fluid volume affects how full and visible superficial veins are, which is why infusion nurses ask about water intake. Drink steadily the day before and the morning of, keep the arm warm on the way in, and eat something so you are not fasting through a two-hour infusion. If you have a documented history of difficult access, say so at check-in rather than after the third attempt, since that history is itself a scored risk factor and often prompts an earlier switch to an ultrasound-guided or more experienced cannulator.

The Symptom Record Your Team Needs

Bring numbers, not impressions. Record daily stool frequency, presence and amount of blood, urgency, nighttime awakenings, abdominal pain, and weight for the weeks since your last dose, along with any days missed from work or school. This matters because symptoms alone are an unreliable guide to inflammation. The AGA recommends a monitoring strategy that pairs symptoms with objective markers, using fecal calprotectin under 150 micrograms per gram and normal CRP to rule out active inflammation in ulcerative colitis, with parallel thresholds of calprotectin under 150 micrograms per gram and CRP under 5 milligrams per liter in Crohn's disease. Infusion visits are a convenient point to draw labs, so ask whether CRP and a calprotectin kit should be added. The 2025 ACG ulcerative colitis guidelines similarly frame monitoring as an integrated assessment of symptoms, endoscopy, biomarkers, and histology aimed at steroid-free remission.

Medications, Reactions, and Infection Since the Last Dose

Bring a current list of every prescription, over-the-counter product, and supplement you take, including doses of prednisone, mesalamine, azathioprine, or methotrexate, and note any course of antibiotics or steroids you needed between visits. Flag anything that suggests an active infection, since serious infections are the principal risk of these drugs and infliximab labeling requires evaluation for active tuberculosis before starting and periodically during therapy. Report any reaction you had during or after a previous infusion. Roughly 20% of infliximab-treated patients experienced an infusion reaction versus 10% on placebo, most occurring during or within one hour of the infusion, while 4% of patients receiving intravenous vedolizumab had an infusion-related reaction compared with 3% on placebo. Also report delayed symptoms such as fever, rash, sore throat, headache, or muscle aches in the days after a dose, particularly if you restarted infliximab after a gap, because serum sickness-like reactions have been observed when therapy is reinstituted after an extended period without treatment.

Questions Worth Asking in the Chair

The infusion nurse is often the clinician you see most often, so use the time. Three questions consistently earn their place:

• Do I still need premedication? Premedication is common but poorly supported. A Spanish cohort of 64 patients and 1,263 infusions found 1.2% infusion reactions with premedication and 1.1% without, and a pediatric case-control study of 105 children and 1,276 infusions concluded premedication did not decrease the incidence of infusion reactions.
• Should we check a trough level? The AGA suggests reactive therapeutic drug monitoring in adults with active IBD on anti-TNF therapy, so bring it up if symptoms returned before the next dose was due.
• Are my vaccines current, and which ones are off-limits? Live vaccines are contraindicated with several of these drugs, and the vedolizumab label directs that patients be brought up to date with all immunizations before treatment.

Closing the Loop After the Appointment

Before you leave the chair, confirm three things in writing: the date and time of the next infusion, any labs ordered and how results will reach you, and any change to dose or interval. Note the infusion start and stop times and the lot number if a biosimilar was used, since biosimilar switches sometimes coincide with a change in how you feel and a dated record makes that easier to evaluate later. Write down anything unusual that happened during the infusion while it is fresh, including flushing, itching, chest tightness, or a headache, and check for delayed symptoms over the following week. That closing note becomes the opening note for the next cycle, and after two or three rounds the pre-infusion summary largely writes itself.